The binding sites for Ang IV have been mapped first in the brain, and the corresponding receptors were named AT4 receptors. Recent evidence suggests the AT4 receptor is the enzyme insulin-regulated aminopeptidase (IRAP). Actions of Ang IV mediated by IRAP include renal vasodilation, hypertrophy and activation of NF-kB leading to increased expression of platelet activator inhibitor-I, monocyte chemoattractant protein, interleukin-6, and tumor necrosis factor-alpha.

References:

1. Swanson, G. N.; Hanesworth, J. M.; Sardinia, M. F.; Coleman, J. K.; Wright, J. W.; Hall, K. L.; Miller-Wing, A. V.; Stobb, J. W.; Cook, V. I.; Harding, E. C.; et al. "Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor." Regul. Pept. 1992, 40, 409–19.
2. Wright, J. W.;  Krebs, L. T.; Stobb, J. W.; Harding, J. W. "The angiotensin IV system: functional implications." Front Neuroendocrinol. 1995, 16, 23–52.
3. Zhuo, J.; Moeller, I.; Jenkins, T.; Chai, S. Y.; Allen, A. M.; Ohishi, M.; Mendelsohn, F. A. "Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors." J. Hypertens. 1998, 16, 2027–37

Related Products: